Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CASP7 | P55210 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.57 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL421063 | 1.00 | KDM4E (0.61) | KDM4EL3MBTL1ADRB2HIF1ATSHR | |
| SCHEMBL421051 | 1.00 | KDM4E (0.61) | KDM4EL3MBTL1ADRB2HIF1ATSHR | |
| SCHEMBL11372834 | 0.85 | AOC3 (0.58) | KDM4EL3MBTL1LMNAKMT2ACYP2D6 | |
| Fepradinol SCHEMBL151235 | 0.83 | KDM4E (0.55) | KDM4EL3MBTL1ADRB2LMNAKMT2A | |
| SCHEMBL21616540 | 0.83 | ADRB2 (0.58) | KDM4EADRB2HIF1ATSHRLMNA | |
| SCHEMBL30534867 | 0.82 | HIF1A (0.68) | KDM4EADRB2HIF1ATSHRLMNA | |
| SCHEMBL28319296 | 0.82 | ADRB2 (0.58) | KDM4EADRB2HIF1ATSHRLMNA | |
| SCHEMBL6464765 | 0.82 | HIF1A (0.68) | KDM4EADRB2HIF1ATSHRLMNA | |
| Fepradinol SCHEMBL29454386 | 0.82 | KDM4E (0.53) | KDM4EL3MBTL1ADRB2LMNAKMT2A | |
| SCHEMBL12205817 | 0.81 | HRH1 (0.52) | ADRB2HIF1ACYP2D6ADRB1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110143886-B | Process for the preparation of beta-arylaminoalkols such as tulobuterol, chlorpropaline, isoadrenaline dichloride and sotalol | 北京化工大学 | 2022-11-01 | — | — | CN | disclosed |
| CN-107021884-B | Method for efficiently synthesizing chiral 1, 2-amino alcohol by catalyzing alpha-aminoketone through Ir/f-amphox | 武汉凯特立斯科技有限公司 | 2019-12-24 | — | — | CN | disclosed |
| CN-110143886-A | The method of the preparation such as beta-aromatic alkamine drug of tulobuterol, Clorprenaline, isoproterenol and Sotalol | 北京化工大学 | 2019-08-20 | — | — | CN | disclosed |
| EP-2173169-A1 | NASAL AND OPHTHALMIC DELIVERY OF AQUEOUS CORTICOSTEROID SOLUTIONS | CyDex Pharmaceuticals, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20090192177-A1 | 2-ARYL pyrrologpyrimidines for A1 and A3 receptors | OSI PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20090082369-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. | 2009-03-26 | — | — | US | disclosed |
| US-7504407-B2 | Compounds specific to adenosine A1 and A3 receptors and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7495028-B2 | R-bambuterol, its preparation and therapeutic uses | TAN, WEN, DR. | 2009-02-24 | — | — | US | disclosed |
| WO-2008005692-A2 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER γ-CYCLODEXTRIN AND CORTICOSTEROID | CYDEX PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| US-7247641-B2 | Compounds, derivatives, compositions, preparation and uses | MGI GP, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247641-B2 | Compounds, derivatives, compositions, preparation and uses | MGI GP, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7160890-B2 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-6898533-B1 | Methods for predicting the biological, chemical, and physical properties of molecules from their spectral properties | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040220749-A1 | Methods for predicting the biological, chemical, and physical properties of molecules from their spectral properties | THE GOVT. OF THE USA AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES | 2004-11-04 | — | — | US | disclosed |
| US-6680324-B2 | 4-AMINO-6-PHENYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2004-01-20 | — | — | US | disclosed |
| EP-0290122-B1 | MORPHOLINE DERIVATIVES AND THEIR USE | BEECHAM GROUP PLC (GB) | 1992-12-23 | — | — | EP | disclosed |
| US-5082840-A | Animal growth regulators | BEECHAM GROUP P.L.C. (GB) | 1992-01-21 | — | — | US | disclosed |
| US-4914202-A | FOR IMPROVING FEED EFFICIENCY IN LIVESTOCK | BEECHAM GROUP P.L.C. (GB) | 1990-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192177-A1 | 2-ARYL pyrrologpyrimidines for A1 and A3 receptors | ADORA3, ADORA1, ADORA2A | KDM4E 4286/4885L3MBTL1 1791/4885ADRB2 264/4885 |
| US-20090082369-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | ADORA3, ADORA2A, ADORA1 | KDM4E 2675/4885L3MBTL1 2250/4885ADRB2 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.